Shingles Vaccine Lowers Dementia Risk in Older Adults

A ground-breaking new study published in the Annals of Internal Medicine offers hopeful news regarding cognitive health. Specifically, researchers evaluated the shingles vaccine dementia risk among vulnerable older adults entering skilled-nursing facilities. Consequently, they found that receiving the recombinant zoster vaccine significantly reduces the likelihood of developing dementia. Furthermore, this study adds robust evidence to a growing body of literature supporting the neuroprotective effects of certain immunizations.

Evaluating the Shingles Vaccine Dementia Risk

To achieve these insights, the investigators conducted a large-scale cohort study using a target trial emulation design. Notably, they analyzed the health records of 509,926 Medicare beneficiaries aged 66 years or older. Additionally, all participants had a recent stay in a skilled-nursing facility and no baseline dementia diagnosis. The researchers then tracked these patients for up to four years. Ultimately, they compared individuals who received at least one dose of the recombinant zoster vaccine (RZV) with unvaccinated peers.

Key Findings on Shingles Vaccine Dementia Risk

The trial results demonstrated a striking protective association. Specifically, vaccinated individuals experienced a 24% lower risk of developing dementia compared to unvaccinated participants. In addition, the vaccinated group had a 5.8 percentage point lower absolute risk of dementia over four years. Indeed, the cumulative risk stood at 18.8% for the vaccinated cohort versus 24.6% for the untreated group. However, the researchers noticed that male patients and individuals with prior live-attenuated shingles vaccination showed a weaker association.

Clinical Implications for Older Adults

Therefore, these findings have profound implications for healthcare providers managing geriatric health. Firstly, the study suggests that the recombinant zoster vaccine provides neuroprotective benefits beyond merely preventing painful shingles. Furthermore, chronic inflammation caused by latent viral infections may drive cognitive decline, making vaccination a key preventive strategy. Consequently, clinicians should actively recommend the recombinant vaccine to eligible older patients, particularly during transition points like skilled-nursing facility admissions. Ultimately, while some residual confounding may exist, this research still highlights a major public health opportunity to reduce dementia burdens.

Frequently Asked Questions

Q1: What did the study find regarding the association between the recombinant shingles vaccine and dementia?

Specifically, vaccinated older adults experienced a 24% lower risk of a dementia diagnosis over four years.

Q2: Why might the shingles vaccine lower the risk of dementia?

Although researchers do not fully understand the exact mechanism, shingles infections trigger significant neuroinflammation and raise stroke risk. Therefore, preventing these infections with the recombinant vaccine may help protect the brain from chronic inflammation and cognitive decline.

Q3: Does the study show the same protective association for everyone?

Notably, the researchers observed a weaker protective association in male patients and prior recipients of the live-attenuated vaccine.

References

1. Hayes KN et al. Dementia Risk After Recombinant Herpes Zoster Vaccination in Older Adults With a Recent Skilled-Nursing Facility Stay : A Target Trial Emulation. Ann Intern Med. 2026 Jun 16. doi: 10.7326/ANNALS-25-04689. PMID: 42296498.
2. dos Reis S et al. Reduced risk of dementia with recombinant zoster vaccine in US adults age 65 or older. Alzheimers Dement. 2026 May 15. doi: 10.1002/alz.14056. PMID: 38753214.
3. Eyting M et al. Causal evidence that herpes zoster vaccination prevents dementia in Wales. Nature Medicine. 2024. doi: 10.1038/s41591-024-03123-x.